Pneumonia Therapeutics Market Forecasted to Grow at a CAGR of 7.3% by 2031, Reaching a Total Worth of USD 5.7 billion | Transparency Market Research, Inc.
19 févr. 2024 05h05 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The pneumonia therapeutics market was valued at US$ 3.0 billion in 2022. A CAGR of 7.3% is...
Healis selected to present at key biotechnology and neuroscience investor conferences in Amsterdam, New York, and San Diego
12 févr. 2024 08h00 HE
|
Healis Therapeutics
Healis' clinical program developing BoNT/A neuromodulator proteins has the potential to transform care for over 280 million patients with depression.
60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer
08 févr. 2024 07h59 HE
|
Sixty Degrees Pharmaceuticals
Kristen Landon appointed Chief Commercial Officer at 60 Degrees Pharma leading ARAKODA® relaunch for malaria prevention and expanded tick-borne strategy.
Gallant Therapeutics Adds Animal Health Executive Aaron Schacht to Board of Directors
06 févr. 2024 08h10 HE
|
Gallant Therapeutics
Gallant Therapeutics Adds Animal Health Executive Aaron Schacht to Board of Directors
Knight Therapeutics Announces Launch of Bijuva® in Canada
06 févr. 2024 07h30 HE
|
Knight Therapeutics
MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a Pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of BIJUVA®...
Digital Therapeutics Market / DTx Market is Expected to Reach $21.9 Billion | MarketsandMarkets™
02 févr. 2024 07h30 HE
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Digital Therapeutics Market / DTx market in terms of revenue was estimated to be worth $6.1 billion in 2023 and is poised to reach $21.9 billion by 2028,...
60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering
31 janv. 2024 11h15 HE
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals (Nasdaq: SXTP) closes $2.4 million public offering.
60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering
30 janv. 2024 09h00 HE
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma announces a $2.4 mil public offering, with funds to be used for working capital, relaunching ARAKODA for malaria prevention, and research
Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology
29 janv. 2024 07h00 HE
|
CYTOMED THERAPEUTICS LIMITED
SINGAPORE, Jan. 29, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary...
Knight Therapeutics Enters into Exclusive License Agreement with Amneal Pharmaceuticals for IPX203
25 janv. 2024 07h30 HE
|
Knight Therapeutics
MONTREAL, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has entered into an...